Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

NGN-PET

Financiado

Cerrado

Modelling Neuron Glia Networks into a drug discovery platform for Pain Efficacio...

Modelling Neuron Glia Networks into a drug discovery platform for Pain Efficacious Treatments Sofia ref. 116072 Chronic Neuropathic Pain is frequently associated with peripheral nerve injury or disease. Peripheral injury activates both neuronal and glial components of the peripheral and central cellular circuitry. While it is widely known t... ver más

31/03/2020

AXXAM

3M€

Presupuesto del proyecto: 3M€

Líder del proyecto

AXXAM SPA No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 6 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2020-03-31

IMI2-2015-07-03: PATHOLOGICAL NEURON-GLIA INTERACTIO...

I+D

Cerrada hace 8 años

0% 49% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

6 Participantes

AXXAM

443.00K€ | Lider

NMI

164.00K€ | Participante

LIFE AND BRAIN GMBH

443.00K€ | Participante

GRT

743.00K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

RTC-2017-6689-1 Identificación y validación de nuevas dianas terapéuticas pa... 644K€ Cerrado

FRESCOatCNAP FrontierResearchCompentences@CNAP 1M€ Cerrado

NEUROPAIN Neuropathic pain biomarkers and druggable targets within th... 9M€ Cerrado

PDC2021-120878-I00 ESTUDIO PRECLINICO DE PRUEBA DE CONCEPTO DE TERAPIAS AVANZAD... 138K€ Cerrado

PAIN-Net Molecule to man pain network 3M€ Cerrado

PROPANE STUDY PROBING THE ROLE OF SODIUM CHANNELS IN PAINFUL NEUROPATHIES 6M€ Cerrado

Duración del proyecto: 35 meses Fecha Inicio: 2017-04-26
Fecha Fin: 2020-03-31

Líder del proyecto

AXXAM SPA No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 3M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Chronic Neuropathic Pain is frequently associated with peripheral nerve injury or disease. Peripheral injury activates both neuronal and glial components of the peripheral and central cellular circuitry. While it is widely known that the subsequently altered interactions between neurons and glial cells contribute to pain development and to its chronification, the underlying mechanisms are poorly understood. Developing mechanism-based therapies targeting neuron-glial interactions to treat chronic pain will be crucial for improving the quality of life of many patients. Hence the development of novel therapeutic solutions represents a major challenge that demands a multi-disciplinary approach to decipher and understand pathological mechanisms and to translate them into predictive tools for drug development. The NGN-PET consortium addresses this challenge by forming a highly interdisciplinary team that builds upon expertise in areas of academic research on pain mechanisms, industrial knowhow on human stem cell-based tool development, HTS technologies and drug discovery. To achieve its goal we will develop preclinical model systems and assays which recapitulate the human in vivo situation and which can be interrogated for the identification, validation of molecular targets and the development new treatments. A focus of the project will be chemotherapy induced NP and the interplay between nociceptors, microglia and Schwann cells. NGN-PET will carefully characterize rodent in vivo and in vitro models to identify these mechanisms, and will develop rat and human iPSCs based in vitro systems of neuron-glial co-cultures that can be interrogated for targets and used for compound identification and validation. NGN-PET will thus pose the basis for the translation of these model systems into high throughput screening platforms for pharmaceutical research and drug discovery.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores